COVIVAXX is a new vaccine candidate to protect against COVID-19. Developed by the Serum Institute of India Pvt. LTD (SIIPL), the globally leading vaccine manufacturer, VPM coordinates the clinical development in Europe. A phase I/II trial is currently ongoing in Australia to assess the safety and immunogenicity of COVIVAXX in humans. A pivotal phase III trial is planned to be conducted in Europe and India in the first half of 2021. Click here to read more.

The local newspaper in Gauteng, South Africa, reported about the priMe study.
Klick here to read the article.

We are pleased to announce that a major milestone in the pivotal phase III trial (trial name: priMe) of the novel tuberculosis vaccine VPM1002 has been achieved with the completed initiation of all clinical trial centers. Read more!

We are happy to announce that Vakzine Projekt Management GmbH (VPM) together with Grit Overseas Pte. Ltd. in Singapore successfully notified a COVID-19 rapid antigen test to the German Institute for Pharmaceuticals and Medical Products (BfArM).

"The DiagnoSure SARS-CoV-2 Antigen Rapid Test is now available and will get reimbursed by the health insurance upon prescription by a doctor.", says Oorvahsk F. Dastoor, Managing Director of Grit Overseas.

The test detects the viral N-protein and is therefore applicable for all virus mutants independent of mutations in their spike protein. This allows a reliable and fast detection of SARS-CoV-2 for everyone.

"We are proud to be involved to make an additional rapid antigen test accessible to the public in this COVID-19 pandemic", says Dr. Leander Grode, Managing Director of VPM. This is the first medicinal product VPM was involved in.